Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis Review

Document Sample
Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					            Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH28958FSA                                                                                          Publication Date: MAR 2013

          55 Network Drive                                   Phone              +1 617 2252500                  Revenue          54.7 (million USD)
          Burlington, MA                                     Fax                +1 617 2252501                  Net Profit       -29.27 (million USD)
          01803                                              Website            www.dyax.com                    Employees        125
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           DYAX [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Dyax Corp. (Dyax) is a fully integrated biopharmaceutical company. It develops and markets of novel biotherapeutics for unmet
       medical needs in the fields of inflammation and oncology. The company's lead product ecallantide is approved under the brand
       name KALBITOR in the US for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.
       Dyax commercialize KALBITOR in the US on its own and through collaborators outside the US. The products and pipeline
       products of the company utilizes its proprietary phage display technology which rapidly selects compounds that bind with high
       affinity and specificity to therapeutic targets.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Dyax Corp., SWOT Analysis
         Gustav A. Christensen               Chief Executive Officer                  Strengths                              Weaknesses
         Henry E. Blair                      Chairman
                                                                                      Licensing and Funded                   Dependence on Third Party
         James W. Fordyce                    Director                                 Research Program                       Manufacturers
         Mary Ann Gray, Ph.D.                Director
                                                                                      Innovative Product and                 History of Losses
         Thomas L. Kempner                   Director                                 Technology
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData
                                                                                      Opportunities                          Threats
       Share Data
         Dyax Corp.                                                                   Robust Pipeline of Products            Competition and Technological
                                                                                                                             Changes
        Share Price (USD) as on 15-Mar-                                  3.97         Increasing Healthcare
        2013                                                                          Expenditure in the US                  Uncertainties in R&D
        EPS (USD)                                                       -0.30
        Market Cap (million USD)                                         395         Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        Enterprise Value (million USD)                                   455
        Shares Outstanding (million)                                     100
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 08, 2013         Dyax's COO Ivana Magovcevic-Liebisch To
                                                                                                           Resign
                                                                                      Feb 13, 2013         Dyax Reports Revenue Of $16m In Q4 2012
                                                                                      Oct 24, 2012         Dyax Reports Revenue Of $13.1m In Q3 2012
                                                                                      Aug 20, 2012         Dyax   Announces            Senior    Management
                                                                                                           Changes
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis                                                                      Reference Code: GDPH28958FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Dyax Corp. - Key Facts ...................................................................................................................................................................... 5
       Dyax Corp. - Key Employees ............................................................................................................................................................. 6
       Dyax Corp. - Key Employee Biographies ........................................................................................................................................... 7
       Dyax Corp. - Major Products and Services......................................................................................................................................... 8
       Dyax Corp. - Pharmaceutical Pipeline Products Data ........................................................................................................................ 9
          Dyax Corp., Pipeline Products by Therapy Area ............................................................................................................................. 9
          Dyax Corp., Pipeline Products by Development Phase ................................................................................................................ 10
       Dyax Corp. - Medical Equipment Pipeline Products Data................................................................................................................. 12
          Dyax Corp. Pipeline Products by Equipment Type ....................................................................................................................... 12
          Dyax Corp. Pipeline Products by Development Stage .................................................................................................................. 14
       Dyax Corp. - History ......................................................................................................................................................................... 16
       Dyax Corp. - Company Statement.................................................................................................................................................... 22
       Dyax Corp. - Locations And Subsidiaries ......................................................................................................................................... 24
          Head Office ................................................................................................................................................................................... 24
          Other Locations & Subsidiaries ..................................................................................................................................................... 24
       Section 2 – Company Analysis ......................................................................................................................................................... 25
       Dyax Corp. - Business Description ................................................................................................................................................... 25
       Dyax Corp. - Corporate Strategy ...................................................................................................................................................... 27
       Dyax Corp. - SWOT Analysis ........................................................................................................................................................... 28
          SWOT Analysis - Overview........................................................................................................................................................... 28
          Dyax Corp. - Strengths ................................................................................................................................................................. 28
             Strength - Licensing and Funded Research Program ............................................................................................................... 28
             Strength - Innovative Product and Technology ......................................................................................................................... 28
             Strength - Strategic Agreements ............................................................................................................................................... 28
          Dyax Corp. - Weaknesses ............................................................................................................................................................ 28
             Weakness - Dependence on Third Party Manufacturers ........................................................................................................... 28
             Weakness - History of Losses ................................................................................................................................................... 29
          Dyax Corp. - Opportunities ........................................................................................................................................................... 29
             Opportunity - Robust Pipeline of Products ................................................................................................................................ 29
             Opportunity - Increasing Healthcare Expenditure in the US ...................................................................................................... 29
             Opportunity - Emerging Markets ............................................................................................................................................... 29
          Dyax Corp. - Threats..................................................................................................................................................................... 30
             Threat - Competition and Technological Changes .................................................................................................................... 30
             Threat - Uncertainties in R&D ................................................................................................................................................... 30
             Threat - Stringent Regulations .................................................................................................................................................. 30
       Dyax Corp. - Key Competitors .......................................................................................................................................................... 31
       Section 3 – Company Financial Ratios ............................................................................................................................................. 32
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 32
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 32
       Performance Chart ........................................................................................................................................................................... 34
       Financial Performance...................................................................................................................................................................... 34


Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis                                                                                                      Reference Code: GDPH28958FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Financial Ratios - Interim Ratios.........................................................................................
				
DOCUMENT INFO
Description: Dyax Corp. (Dyax) is a fully integrated biopharmaceutical company. It develops and markets of novel biotherapeutics for unmet medical needs in the fields of inflammation and oncology. The company's lead product ecallantide is approved under the brand name KALBITOR in the US for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. Dyax commercialize KALBITOR in the US on its own and through collaborators outside the US. The products and pipeline products of the company utilizes its proprietary phage display technology which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.